GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NIOX Group PLC (OTCPK:CSSPF) » Definitions » Valuation Rank

NIOX Group (NIOX Group) Valuation Rank


View and export this data going back to 2014. Start your Free Trial

What is NIOX Group Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

NIOX Group Valuation Rank Related Terms

Thank you for viewing the detailed overview of NIOX Group's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

NIOX Group (NIOX Group) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NIOX Group PLC (OTCPK:CSSPF) » Definitions » Valuation Rank
Comparable Companies
LSE:MXCT LSE:EKF LSE:CREO LSE:BELL LSE:IUG LSE:IHC LSE:POLX LSE:SUN LSE:MHC LSE:DEMG ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
NIOX:UK 82C:Germany
Address
Edmund Halley Road, Hayakawa Building, The Oxford Science Park, Oxford, GBR, OX4 4GB
Website
https://investors.niox.com
NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.